

INTEGRA NEUROSCIENCES LIMITED
(Company Number: 02086419)

**WRITTEN DIRECTORS' RESOLUTION APPROVING AND
ADOPTING THE CARBON REDUCTION PLAN AND
AUTHORISING ITS PUBLICATION**

Date: 8 October 2026

Background

The undersigned, being all the directors of Integra NeuroSciences Limited (the Company) entitled to participate in the decision and acting unanimously pursuant to the Company's articles of association, hereby make the following decisions as directors of the Company.

A Carbon Reduction Plan dated 8 October 2026 (the CRP) has been prepared for the Company as the relevant UK bidding entity in connection with applicable UK public procurement requirements, including Procurement Policy Note 006, as updated in February 2025, and any relevant NHS procurement requirements.

The directors have reviewed the CRP attached to this resolution as Annexure 1, including its reporting boundary, stated emissions data and estimates, proposed carbon reduction measures and the Company's commitment to achieving Net Zero greenhouse gas emissions by 2050. In reaching the decisions below, each director has exercised independent judgment and had regard to the matters set out in section 172(1) of the Companies Act 2006, including the likely long-term consequences of the decision, the Company's business relationships, the impact of its operations on the community and the environment, and the desirability of maintaining a reputation for high standards of business conduct, and considers the decisions to be in the best interests of the Company.

Resolutions

1. Approval of Carbon Reduction Plan

The Carbon Reduction Plan attached as Annexure 1 to these resolutions be and is hereby approved and adopted by the Company.

2. Adoption of Net Zero Commitment

The Company confirms and adopts the commitment set out in the CRP to achieve Net Zero greenhouse gas emissions by 2050. The directors acknowledge that the CRP contains an interim UK-specific emissions assessment and that UK-specific reduction targets and measures will be developed and updated following validation of the baseline data, as described in the CRP.

3. Board Approval Statement

The directors confirm that the Carbon Reduction Plan has been reviewed by the Board and approve the inclusion within the Carbon Reduction Plan of the statement that the plan has been reviewed and approved by the Board of Directors of Integra NeuroSciences Limited.

4. Authority to Sign and Publish

Any director of the Company is authorised to sign the CRP on behalf of the Company and, to the extent permitted by the Company's articles of association, to authorise an appropriate officer or employee to complete and submit the CRP. Any director is also authorised to approve non-material, administrative or factual amendments that do not alter the Company's Net Zero commitment, reporting boundary, material emissions figures or substantive reduction measures; to arrange publication of the final CRP on the Company's UK website; to submit it for relevant NHS or other UK public procurement purposes; and to take any other action necessary or desirable to give effect to these resolutions. Any material amendment to those matters must be referred back to the Board for approval.

5. Ratification

All actions taken by any director, officer, employee or adviser of the Company in connection with the preparation, review or implementation of the Carbon Reduction Plan before the date of these resolutions are hereby ratified, approved and confirmed.

6. Records and Counterparts

These resolutions may be evidenced by counterparts or by electronic approval from each eligible director. Once approved by all eligible directors, they shall take effect on the date on which the last director approves them and shall be retained with the Company's records in accordance with section 248 of the Companies Act 2006.

Directors' Approval

Director	Signature / Email Approval	Date
Jeffrey Mosebrook	Email Approval	8 th October, 2026
Timothy Swiss	Email Approval	12 th October, 2026

Annexure 1

Carbon Reduction Plan

Supplier name: Integra NeuroSciences Ltd

Publication date: 8 October 2026

Commitment to achieving net zero

Integra NeuroSciences Ltd is committed to achieving net zero emissions by 2050.

Baseline emissions footprint

As 2025 represents the first year in which emissions have been assessed specifically for Integra NeuroSciences Ltd's UK reporting boundary, 2025 has been adopted as both the baseline year and current reporting year. Future performance will be measured against the validated 2025 baseline.

Baseline year: 2025

Additional details relating to the baseline emissions calculations:

Historically, Integra LifeSciences has reported its greenhouse gas emissions on a global organisational basis through its corporate sustainability and ESG reporting. These disclosures have provided visibility of emissions across the wider Integra LifeSciences group, including its international operations and value chain.

Integra NeuroSciences Ltd has now committed to establishing a dedicated UK reporting boundary to provide a more accurate and transparent account of the emissions associated with the UK bidding entity and its activities supporting NHS customers.

This UK-specific Carbon Reduction Plan will operate alongside Integra LifeSciences' global emissions reporting. It does not replace the group's global disclosures or Net Zero commitments but provides an additional level of reporting focused specifically on Integra NeuroSciences Ltd and its UK operations.

The commitment to achieving Net Zero greenhouse gas emissions by 2050 is supported and adopted by Integra NeuroSciences Ltd. The carbon reduction measures contained within this plan will apply to the UK bidding entity and, where relevant, to the delivery of NHS contracts.

Integra NeuroSciences Ltd is working in partnership with Auditel, a professional carbon accounting and decarbonisation specialist, to establish the UK reporting boundary, calculate

the January–December 2025 emissions dataset and develop a robust, repeatable annual reporting process.

Baseline year emissions	
Emissions	Total (tCO ₂ e)
Scope 1	0.00 tCO ₂ e (actual)
Scope 2	0.00 tCO ₂ e (actual)
Scope 3 (included sources)	389.19 tCO ₂ e (estimate)
3.3 Fuel and Energy related Activities	0.00 tCO ₂ e (actual)
3.4 Upstream Transport & Distribution	75.00 tCO ₂ e (estimate)
3.5 Waste	0.00 tCO ₂ e (actual)
3.6 Business Travel	175.00 tCO ₂ e (estimate)
3.7 Employee Commuting (inc. WTT) and homeworking	14.19 tCO ₂ e (estimate)
3.9 Downstream Transport & Distribution	125.00 tCO ₂ e (estimate)
Sources included	Upstream Transportation and Distribution, Waste generated in operations, Business Travel, Employee Commuting, Home Working, Downstream Transportation and Distribution
Total emissions	389.19 tCO ₂ e

Current emissions reporting

Reporting year: 2025

Current emissions	
Emissions	Total (tCO ₂ e)
Scope 1	0.00 tCO ₂ e (actual)
Scope 2	0.00 tCO ₂ e (actual)
Scope 3 (included sources)	389.19 tCO ₂ e (estimate)
3.3 Fuel and Energy related Activities	0.00 tCO ₂ e (actual)
3.4 Upstream Transport & Distribution	75.00 tCO ₂ e (estimate)
3.5 Waste	0.00 tCO ₂ e (actual)
3.6 Business Travel	175.00 tCO ₂ e (estimate)
3.7 Employee Commuting (inc. WTT) and homeworking	14.19 tCO ₂ e (estimate)
3.9 Downstream Transport & Distribution	125.00 tCO ₂ e (estimate)
Sources included	Upstream Transportation and Distribution, Waste generated

	in operations, Business Travel, Employee Commuting, Home Working, Downstream Transportation and Distribution
Total emissions	389.19 tCO₂e

Integra NeuroSciences Ltd does not operate a dedicated UK office or directly consume natural gas, purchased electricity or company-controlled fuel within the defined UK reporting boundary. Scope 1, Scope 2, fuel and energy-related activities and operational waste have therefore been reported as 0.00 tCO₂e for this interim assessment.

Most emissions associated with the UK entity are anticipated to arise within Scope 3, including transportation and distribution, business travel, employee commuting and waste generated in operations.

The emissions presented below constitute an interim UK-specific disclosure. They are based on preliminary and partially estimated activity data and have not yet undergone full validation or verification against the GHG Protocol Corporate Standard.

Where estimates have been necessary, these have been calculated using one or more of the following:

- Extrapolated activity data
- Available financial or reimbursement records
- Supplier information and assumptions
- Recognised industry-average data
- Appropriate UK Government greenhouse gas conversion factors
- Incomplete Scope 3 datasets that are currently being reviewed and refined

These estimates will be replaced or updated with more accurate activity-based and supplier-specific data wherever this becomes available. A fully validated UK Carbon Reduction Plan, incorporating the confirmed January–December 2025 emissions dataset, updated carbon reduction measures and appropriate reduction targets, will be published during the 2026 reporting cycle.

This approach will enable Integra NeuroSciences Ltd to improve the accuracy, transparency and completeness of its UK carbon reporting while continuing to report in tandem with the wider global requirements and commitments of Integra LifeSciences.

Emissions reduction targets

Integra NeuroSciences Ltd is committed to developing UK-specific emissions reduction targets following completion and validation of its dedicated UK emissions baseline. These targets will reflect the emissions sources within the UK reporting boundary and will focus particularly on the material Scope 3 categories identified through the carbon accounting process.

The UK targets and associated carbon reduction measures will be developed during the 2026 reporting cycle and incorporated into the next annual update of this Carbon Reduction Plan. Progress will then be monitored and reported annually against the confirmed UK baseline.

This UK-specific approach will operate alongside, and remain aligned with, the wider environmental commitments and global decarbonisation strategy of Integra LifeSciences. At a global level, Integra LifeSciences has been developing a decarbonisation roadmap to establish greenhouse gas reduction goals, key milestones and a timeline for reducing emissions. This work includes reviewing relevant policies, strengthening emissions data collection and establishing processes through which progress can be tracked.

Further information regarding Integra LifeSciences' global environmental commitments, targets and progress is provided within its corporate ESG reporting.

Carbon reduction projects

Completed carbon reduction initiatives

Integra LifeSciences continues to implement environmental and carbon reduction initiatives across its global operations.

In 2023, Integra completed the installation of solar panels at its Rietheim-Weilheim site in Germany, supporting the increased use of renewable energy within its operations.

Integra also partnered with an external energy consultant to undertake pilot energy assessments at three of its highest-energy-using sites. These assessments identified opportunities to improve energy efficiency and reduce consumption, with recommendations beginning to be implemented at the Añasco site in Puerto Rico.

Further information on Integra LifeSciences' completed environmental initiatives and progress is available within its corporate ESG reporting.

Future carbon reduction initiatives

At a global level, Integra LifeSciences has been developing a decarbonisation roadmap to establish greenhouse gas reduction goals, identify key milestones and strengthen the processes used to collect data, monitor performance and track progress.

Alongside these global activities, Integra NeuroSciences Ltd is establishing a dedicated UK emissions baseline and carbon reduction programme. Following validation of the UK footprint, priority reduction opportunities will be identified across the most material emissions categories.

Initial areas for assessment will include:

- Transportation and distribution

- Business travel
- Employee commuting and homeworking
- Supplier engagement and data quality
- Opportunities to improve activity-based emissions reporting

UK-specific initiatives, targets and progress will be included within future annual updates to this Carbon Reduction Plan.

Declaration and sign-off

This Carbon Reduction Plan has been completed in accordance with PPN 006 and the associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard and uses the appropriate government emission conversion factors for greenhouse gas company reporting.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements (where required), and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors.

Signed on behalf of the supplier:



.....
Date: 8 October 2026